#200: Insulin and QWINT-1 Trial in T2DM: Beyond Journal Club Segment with NEJM Group
Core IM | Internal Medicine Podcast
Core IM Team
4.8 • 1.2K Ratings
🗓️ 11 February 2026
⏱️ 29 minutes
🧾️ Download transcript
Summary
From metformin to basal insulin to overlooked older medications, this episode reviews the T2D medication toolkit clinicians use every day. We then dive into new evidence on once-weekly insulin to help you individualize therapy while reducing treatment burden.
🔹 Sponsor: Pain Management and Opioids Adaptive Learning Free Online Course by NEJM Group: https://cme-info.nejm.org/core-im/
00.58 | Insulin Hx & Types
06:00 | Indications for Insulin and the Burden on Patients
08:26 | What is the QWINT-1 Trial?
16:18 | Discussion
Tags: CoreIM, Internal Medicine, Evidence-Based Medicine, Insulin Resistance, Clinical Reasoning, Hospital Medicine, Medical Education, Endocrine, Endocrinology
Find the best disability insurance for you: https://www.patternlife.com/disability-insurance?campid=497840
Our Sponsors:
* Check out Branch Basics and use my code branchbasics.com/COREIM for a great deal: https://branchbasics.com
* Check out FIGS and use my code FIGSRX for a great deal: https://wearfigs.com
* Check out Quince for high-quality clothes with affordable pricing and use code quince.com/coreim
Advertising Inquiries: https://redcircle.com/brands
Privacy & Opt-Out: https://redcircle.com/privacy
Transcript
Click on a timestamp to play from that location
| 0:00.0 | Just a quick message from our sponsor. |
| 0:02.3 | Like most of us, when I first heard about the DEA mate requirement of eight hours of training, |
| 0:07.0 | my first reaction was like, great, just another hoop to jump through. |
| 0:10.4 | But then I learned about the pain management and opioids adaptive learning program from any jam group. |
| 0:15.3 | It's free and it's actually turned that requirement to something engaging and useful. |
| 0:19.8 | The course is interactive, |
| 0:21.4 | 62 case-based questions, videos, infographics that walk you through the complexities of pain |
| 0:26.8 | management, opioid prescribing, and substance use. You walk away not just by being compliant |
| 0:31.4 | with requirements, but sharper for your patients. You earn 10.25 CME credits along with it and ABIMMOC points. So if you have to spend the time, why not make it count? You can check it out and we'll link it in our show notes at CME-info. N-JM.org slash core-dash-I-M. And with that, let's get back to the episode. |
| 0:52.0 | Welcome to Beyond Journal Club, a collaboration between Core I.M and NEJM group. The goal of Beyond Journal Club is to take landmark clinical trials and put them into context, telling the story of how we got to where we are and what it means to take care of our patients. I'm Dr. Shreda Truvetti. I'm an internist at Vyat EMC. I'm Dr. Greg Katz, cardiologist at NYU. And I'm Dr. Clem Lee, a med-piece hospitalist in Boston, and a guest editor at any jam. |
| 1:13.9 | I'm Dr. Lak Katz, cardiologist at NYU. And I'm Dr. Clem Lee, a med-Piz hospitalist in Boston, and a guest |
| 1:12.8 | editor at N-E-J-M. I'm Dr. Lakshmiravindra, endocrinologist, and N-JM editorial fellow. Today, we're |
| 1:19.7 | diving into the rapidly changing world of diabetes to look at the Quint One trial. This investigated |
| 1:25.9 | once-weekly insulin F-sitora in people with type 2 diabetes |
| 1:30.1 | and was published in the New England Journal of Medicine in June of 2025. And before getting |
| 1:36.2 | into the Quint One trial, we'll review different types of insulin we have available and when |
| 1:40.8 | we should be reaching for insulin in the first place. And then finally, we'll dive into the Quint One trial |
| 1:45.4 | and talk about how once-weekly insulin may fit into our landscape of diabetic treatment options. |
| 1:56.0 | So I feel like I need to come clean because all of these insulin options |
| 1:59.8 | honestly make me feel like I don't know anything about all of these insulin options honestly make me feel |
| 2:00.8 | like I don't know anything about endocrinology at all. It's really confusing. Short acting, long |
| 2:05.3 | acting, rapid acting, intermediate acting. They all have different brand names. Learning insulin |
... |
Please login to see the full transcript.
Disclaimer: The podcast and artwork embedded on this page are from Core IM Team, and are the property of its owner and not affiliated with or endorsed by Tapesearch.
Generated transcripts are the property of Core IM Team and are distributed freely under the Fair Use doctrine. Transcripts generated by Tapesearch are not guaranteed to be accurate.
Copyright © Tapesearch 2026.